Suppr超能文献

与大麻合法化相关的六条政策经验教训。

Six policy lessons relevant to cannabis legalization.

机构信息

Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.

Department of Psychiatry and Behavioral Sciences, Veterans Affairs Health Care System and Stanford University, Palo Alto, CA, USA.

出版信息

Am J Drug Alcohol Abuse. 2019;45(6):698-706. doi: 10.1080/00952990.2019.1569669. Epub 2019 Mar 14.

Abstract

Cannabis (marijuana) has been legalized for recreational and/or medicinal use in many US states, despite remaining a Schedule-I drug at the federal level. As legalization regimes are established in multiple countries, public health professionals should leverage decades of knowledge from other policy areas (e.g., alcohol and tobacco regulation) to inform cannabis policy. Identify policy lessons from other more established policy areas that can inform cannabis policy in the United States, Canada, and any other nations that legalize recreational cannabis. Narrative review of policy and public health literature. We identified six key lessons to guide cannabis policy. To avoid the harms of "a medical system only in name," medical cannabis programs should either be regulated like medicine or combined with the recreational market. Capping potency of cannabis products can reduce the harms of the drug, including addiction. Pricing policies that promote public health may include minimum unit pricing or taxation by weight. Protecting science and public health from corporate interest can prevent the scenarios we have seen with soda and tobacco lobbies funding studies to report favorable results about their products. Legalizing states can go beyond reducing possession arrests (which can be accomplished without legalization) by expunging prior criminal records of cannabis-related convictions. Finally, facilitating rigorous research can differentiate truth from positive and negative hype about cannabis' effects. Scientists and policymakers can learn from the successes and failures of alcohol and tobacco policy to regulate cannabis products, thereby mitigating old harms of cannabis prohibition while reducing new harms from legalization.

摘要

尽管大麻(大麻)在联邦一级仍被归类为附表 I 药物,但在美国许多州已将其合法化用于娱乐和/或药用。随着多个国家建立合法化制度,公共卫生专业人员应该利用其他政策领域(例如,酒精和烟草监管)数十年的知识为大麻政策提供信息。从其他更成熟的政策领域中汲取经验教训,为美国、加拿大和任何其他合法化娱乐性大麻的国家的大麻政策提供信息。对政策和公共卫生文献的叙述性回顾。我们确定了六个关键的经验教训来指导大麻政策。为了避免“徒有其名的医疗体系”造成的危害,医用大麻计划要么像药品一样受到监管,要么与娱乐市场相结合。限制大麻产品的效力可以减少药物的危害,包括成瘾。促进公共健康的定价政策可能包括最低单位定价或按重量征税。保护科学和公共卫生免受企业利益的影响,可以防止我们在苏打水和烟草游说团体资助研究以报告其产品有利结果方面看到的情况。合法州可以通过清除与大麻相关的定罪的先前犯罪记录,超越减少持有逮捕(可以在不合法的情况下完成)。最后,促进严格的研究可以区分大麻效应的真相与积极和消极的炒作。科学家和政策制定者可以从酒精和烟草政策的成功和失败中吸取教训,规范大麻产品,从而减轻大麻禁令的旧有危害,同时减少合法化带来的新危害。

相似文献

1
Six policy lessons relevant to cannabis legalization.
Am J Drug Alcohol Abuse. 2019;45(6):698-706. doi: 10.1080/00952990.2019.1569669. Epub 2019 Mar 14.
2
3
Evaluating the public health impacts of legalizing recreational cannabis use in the United States.
Addiction. 2016 Oct;111(10):1764-73. doi: 10.1111/add.13428. Epub 2016 Jun 7.
4
Cannabis legalization, regulation, & control: a review of key challenges for local, state, and provincial officials.
Am J Drug Alcohol Abuse. 2019;45(6):689-697. doi: 10.1080/00952990.2019.1611840. Epub 2019 May 28.
6
Assessing New Zealand's Cannabis Legalization and Control Bill: prospects and challenges.
Addiction. 2021 Feb;116(2):222-230. doi: 10.1111/add.15144. Epub 2020 Jul 4.
7
Exploring the effect of Colorado's recreational marijuana policy on opioid overdose rates.
Public Health. 2020 Aug;185:8-14. doi: 10.1016/j.puhe.2020.04.007. Epub 2020 Jun 3.
8
Implementing social justice in the transition from illicit to legal cannabis.
Am J Drug Alcohol Abuse. 2019;45(6):673-688. doi: 10.1080/00952990.2019.1674862. Epub 2019 Oct 21.
9
Public health implications of legalising the production and sale of cannabis for medicinal and recreational use.
Lancet. 2019 Oct 26;394(10208):1580-1590. doi: 10.1016/S0140-6736(19)31789-1. Epub 2019 Oct 23.
10
Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts.
Int J Health Policy Manag. 2016 Aug 1;5(8):453-456. doi: 10.15171/ijhpm.2016.63.

引用本文的文献

1
2
Prevalence of cannabidiol use and correlates in U.S. adults.
Drug Alcohol Depend Rep. 2024 Oct 9;13:100289. doi: 10.1016/j.dadr.2024.100289. eCollection 2024 Dec.
3
Evaluations of State Medical Cannabis Programs in the USA: A Narrative Review.
Med Cannabis Cannabinoids. 2024 Nov 6;7(1):243-256. doi: 10.1159/000542472. eCollection 2024 Jan-Dec.
4
Highs and Lows: A Mixed-Methods Analysis of the Impact of Adult Use Legalization on Medical Cannabis Patients.
J Psychoactive Drugs. 2024 Nov 21:1-10. doi: 10.1080/02791072.2024.2430608.
5
A Review of Meta-Analyses of Prevention Strategies for Problematic Cannabis Use.
Curr Addict Rep. 2024 Oct;11(5):886-893. doi: 10.1007/s40429-024-00592-w. Epub 2024 Jul 24.
6
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.
Annu Rev Psychol. 2025 Jan;76(1):143-165. doi: 10.1146/annurev-psych-020124-023532. Epub 2024 Dec 3.
9
Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
Addiction. 2025 Feb;120(2):201-206. doi: 10.1111/add.16575. Epub 2024 Jun 6.
10
Trends in U.S. Medical Cannabis Registrations, Authorizing Clinicians, and Reasons for Use From 2020 to 2022.
Ann Intern Med. 2024 Apr;177(4):458-466. doi: 10.7326/M23-2811. Epub 2024 Apr 9.

本文引用的文献

2
Cannabis Legalization in Canada: Reflections on Public Health and the Governance of Legal Psychoactive Substances.
Front Public Health. 2018 Aug 6;6:220. doi: 10.3389/fpubh.2018.00220. eCollection 2018.
4
Medical Marijuana Users are More Likely to Use Prescription Drugs Medically and Nonmedically.
J Addict Med. 2018 Jul/Aug;12(4):295-299. doi: 10.1097/ADM.0000000000000405.
5
The Association of Unfavorable Traffic Events and Cannabis Usage: A Meta-Analysis.
Front Pharmacol. 2018 Feb 12;9:99. doi: 10.3389/fphar.2018.00099. eCollection 2018.
6
Regulating Cannabis Manufacturing: Applying Public Health Best Practices from Tobacco Control.
J Psychoactive Drugs. 2018 Jan-Mar;50(1):19-32. doi: 10.1080/02791072.2017.1422816. Epub 2018 Feb 13.
7
Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands.
Psychol Med. 2018 Oct;48(14):2346-2352. doi: 10.1017/S0033291717003877. Epub 2018 Jan 31.
8
Extending Addiction's conflict of interest policy to cover the emerging cannabis industry.
Addiction. 2018 Feb;113(2):205. doi: 10.1111/add.14098. Epub 2017 Dec 5.
9
Potency increase, product development and marijuana marketing in times of legalization.
Addiction. 2017 Dec;112(12):2178-2179. doi: 10.1111/add.13945.
10
Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States.
Am J Psychiatry. 2018 Jan 1;175(1):47-53. doi: 10.1176/appi.ajp.2017.17040413. Epub 2017 Sep 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验